Eyevance Pharmaceuticals

OverviewSuggest Edit

Eyevance Pharmaceuticals is a company that develops ophthalmic therapies for the ocular surface and anterior segment. It offers products for inflammatory ocular conditions, ocular itch, ocular surface inflammation, fungal infections, and dry eye symptoms.

TypePrivate
Founded2017
HQFort Worth, TX, US
Websiteeyevance.com

Latest Updates

Employees (est.) (Apr 2021)67(-2%)
Cybersecurity ratingAMore

Key People/Management at Eyevance Pharmaceuticals

Jerry St. Peter

Jerry St. Peter

Co-Founder, CEO and Director
Jason Werner

Jason Werner

Co-Founder and COO
Wes Brazell

Wes Brazell

Chief Financial Officer
Mark Jasek

Mark Jasek

Chief Scientific Officer
Julie Speed

Julie Speed

Chief Commercial Officer
Jodi Luchs

Jodi Luchs

Co-Chief Medical Officer
Show more

Eyevance Pharmaceuticals Office Locations

Eyevance Pharmaceuticals has an office in Fort Worth
Fort Worth, TX, US (HQ)
777 Taylor St #1050
Fort Worth, TX, US
Wells Fargo Tower, 201 Main St 6th floor
Show all (2)

Eyevance Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2017

Eyevance Pharmaceuticals total Funding

$30 k

Eyevance Pharmaceuticals latest funding size

$30 k

Time since last funding

2 years ago
Eyevance Pharmaceuticals's latest funding round in November 2019 was reported to be $30 k. In total, Eyevance Pharmaceuticals has raised $30 k
Show all financial metrics

Eyevance Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Eyevance Pharmaceuticals Online and Social Media Presence

Embed Graph

Eyevance Pharmaceuticals News and Updates

Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive U.S licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd, has entered into a partnership with Hikma Pharmaceuticals for the co-promotion…

Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement

Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”) and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance P…

Eyevance Pharmaceuticals Launches ZERVIATE™ in the United States

Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the United States launch of ZERVIATE™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis. ZERVIAT…

Eyevance Pharmaceuticals Frequently Asked Questions

  • When was Eyevance Pharmaceuticals founded?

    Eyevance Pharmaceuticals was founded in 2017.

  • Who are Eyevance Pharmaceuticals key executives?

    Eyevance Pharmaceuticals's key executives are Jerry St. Peter, Jason Werner and Wes Brazell.

  • How many employees does Eyevance Pharmaceuticals have?

    Eyevance Pharmaceuticals has 67 employees.

  • Who are Eyevance Pharmaceuticals competitors?

    Competitors of Eyevance Pharmaceuticals include Bio-Tissue, Kedalion Therapeutics and Alkeus Pharmaceuticals.

  • Where is Eyevance Pharmaceuticals headquarters?

    Eyevance Pharmaceuticals headquarters is located at 777 Taylor St #1050, Fort Worth.

  • Where are Eyevance Pharmaceuticals offices?

    Eyevance Pharmaceuticals has an office in Fort Worth.

  • How many offices does Eyevance Pharmaceuticals have?

    Eyevance Pharmaceuticals has 2 offices.